9th Mar 2021 17:30
RTW Venture Fund Ltd - New York-based investment company focussed on life sciences - Takes part in USD36 million Series A financing round for clinical stage pharmaceutical company Visus Therapeutics Inc, which developers presbyobia-correcting eye drops.
Visus will use the proceeds to advance the clinical development program for its lead asset BRIMOCHOL.
Also partook in USD114 million financing round for biotech firm Ventyx Biosciences Inc, which is advancing a pipeline of novel small molecule therapeutics for patients with inflammatory and autoimmune diseases.
Pipeline programmes include a selective allosteric TYK2 inhibitor for a broad range of immunological disorders, a tissue selective S1P1R modulator for inflammatory bowel disease, and a preclinical NLRP3 inhibitor program.
Current stock price: USD2.34, closed up 4.5% on Tuesday
Year-to-date change: up 25%
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Rtw Biotech